Analysts Set Korro Bio, Inc. (NASDAQ:KRRO) PT at $144.00

Korro Bio, Inc. (NASDAQ:KRRO) has received a consensus rating of “Buy” from the seven analysts that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $144.00.

A number of analysts recently weighed in on the company. Oppenheimer assumed coverage on Korro Bio in a research report on Friday, January 10th. They issued an “outperform” rating and a $155.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $115.00 target price on shares of Korro Bio in a research report on Friday, November 22nd. Finally, William Blair restated an “outperform” rating on shares of Korro Bio in a research report on Wednesday, November 13th.

Institutional Trading of Korro Bio

Several hedge funds and other institutional investors have recently bought and sold shares of KRRO. Quest Partners LLC lifted its position in Korro Bio by 172.1% in the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock valued at $59,000 after purchasing an additional 1,124 shares during the last quarter. Brown Brothers Harriman & Co. lifted its position in Korro Bio by 251.0% in the third quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock valued at $95,000 after purchasing an additional 2,041 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Korro Bio by 1,018.2% during the third quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company’s stock valued at $164,000 after buying an additional 4,470 shares during the period. MetLife Investment Management LLC increased its stake in shares of Korro Bio by 129.0% during the third quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock valued at $122,000 after buying an additional 2,050 shares during the period. Finally, State Street Corp increased its stake in shares of Korro Bio by 18.9% during the third quarter. State Street Corp now owns 118,765 shares of the company’s stock valued at $3,969,000 after buying an additional 18,877 shares during the period. Institutional investors own 13.18% of the company’s stock.

Korro Bio Stock Performance

NASDAQ:KRRO opened at $25.07 on Friday. The business has a 50 day moving average of $35.01 and a 200 day moving average of $43.79. Korro Bio has a 1-year low of $24.11 and a 1-year high of $98.00.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).